pre-ipo
Stage
About
RAPT Therapeutics is a clinical-stage immunology-focused biopharmaceutical company developing novel therapies, including a half-life extended monoclonal antibody targeting free IgE, to treat inflammatory, immunologic, and allergic diseases such as food allergies and chronic spontaneous urticaria.
Explore RAPT Therapeutics's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.